Company announcement no. 10 – 25 10 November 2025 NTG Nordic Transport Group publishes interim report for Q3 2025 The interim report for Q3 2025 is enclosed. In connection with publication of the results for Q3 2025, a conference call will be hosted on 11 November 2025 at 10:00 AM CET. The conference call will be held in English and can be followed live via NTG’s website; investor.ntg.com. Additional information For additional information, please contact:Investor relations and press:Sebastian Rosborg,Head of Investor Relations & External Communications +45 42 12 80 99 Sebastian.rosborg@ntg.com ir@ntg.com|press@ntg.com   Attachments NTG Interim Report Q3 2025AttachmentsCompany announcement no. 10_2025NTG Interim Report Q3 2025

PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. HighlightsProgressed clinical development of tecarfarin.Completed the manufacturing of tecarfarin drug product in accordance with current good manufacturing practices (cGMP). Ongoing activities in support of a single-site U.S. Phase 2 study of tecarfarin in LVAD patients as part of the collaboration agreement with Abbott. Investigator discussions for a potential multi-site Phase 2 study of tecarfarin in dialysis patients...

ASHBURN, Va., Nov. 10, 2025 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, has posted its 2025 third quarter financial results on its investor relations website at https://investors.telos.com. Telos will host a live webcast to discuss its third quarter 2025 financial results today, November 10, 2025, at 9:30 a.m. ET. To access the webcast, visit https://edge.media-server.com/mmc/p/fsjkyffa/lan/en. Related presentation materials will be made available on the Investors section of the Company’s website at https://investors.telos.com. In addition, an archived webcast will be available approximately two hours after the conclusion of the live event on the Investors section of the Company’s website.  About Telos...

SINGAPORE, Nov. 10, 2025 (GLOBE NEWSWIRE) — Currenc Group Inc. (Nasdaq: CURR) (“Currenc” or the “Company”), a fintech pioneer empowering financial institutions worldwide with artificial intelligence (AI) solutions, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial HighlightsTotal Processing Value (TPV) through Tranglo was US$1.41 billion for the third quarter of 2025, increasing by 10.1%1 year-over-year. Total number of transactions increased to 3.0 million for the third quarter of 2025 from 2.7 million for the same period of 2024.Total revenues, excluding TNG Asia and GEA2, were US$10.4 million for the third quarter of 2025, representing a year-over-year decrease of 3.9%3, primarily due to lower Indonesian Airtime revenue, partly offset by growth in...

Conference Call Today at 10:00 a.m. Eastern Standard Time Investor Day Scheduled for March 19, 2026, at the new Nashville, TN Campus PARSIPPANY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (Nasdaq: LINC) today announced financial and operating results for the third quarter ended September 30, 2025, as well as recent business developments. Third Quarter Financial and Operational Highlights(Quarter ended September 30, 2025, compared to the quarter ended September 30, 2024, unless otherwise noted) Financial PerformanceRevenue increased $27.0 million, or 23.6% to $141.4 million, or 25.4% excluding the Transitional segment Net income of $3.8 million, or $0.12 per share, compared to $4.0 million, or $0.13 per share last year, when the quarter included a $2.8 million one-time insurance gain Adjusted...

Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive at least $50 million from cost sharing  Announced positive long-term safety and efficacy data with 1.5 to 2 years of follow-up from the Phase 1/2 PRISM clinical trial in wet AMD  Completed equity offering providing net proceeds of ~$93 million   Announced up to $11 million equity investment from the Cystic Fibrosis Foundation to accelerate development of 4D-710 for cystic fibrosis into Phase 2   $372 million in cash, cash equivalents and marketable securities as of September 30, 2025, combined with upfront and expected cost sharing from Otsuka partnership and ~$93 million in net proceeds from equity offering, expected to fund currently planned...

Third Quarter 2025 Revenue of $30.3 million; Net Income of $17.0 million OMAHA, Neb., Nov. 10, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus”), a leading self-custodial cryptocurrency platform, today announced its unaudited results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights (Unaudited)In USD millions, except percentages Q3 2025 Q3 2024   % ChangeRevenue   $30.3     $20.1   51 %Technology, development and user support   17.0     11.3   50 %General and administrative   14.9     8.5   75 %(Gain) loss on digital assets, net   (21.0 )   0.4   (5,350 %)Net income   17.0     0.8   2,025 %                 In addition, the company announced earlier today that it has acquired Grateful, a stablecoin payments orchestrator for merchants...

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended September 30, 2025 and provided a corporate update. “With a number of data events expected in the coming months, we remain focused on advancing our programs in chronic urticaria and continue to believe that briquilimab has the potential to serve as a highly differentiated therapeutic in mast cell disease based on the results we’ve generated thus far,” said Ronald Martell, President and Chief Executive Officer of Jasper....

Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025 Expect to present interim analysis from approximately 25 six-month evaluable BCG-Unresponsive NMIBC patients in the ongoing ADVANCED-2 trial in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support now expected by year-end 2025 Cash, cash equivalents and investments of approximately $134 million as of September 30, 2025, expected to support planned operations into mid-2027NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results...

Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA) Completed $15 million registered direct offering and $125 million private placement with potential for up to an additional $165 million upon full warrant exercise Completed pivotal phase 3 DRAGON trial in Stargardt disease (STGD); final topline data expected in Q4 2025 China’s NMPA has agreed to accept New Drug Application with priority review for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results of DRAGON trial UK’s MHRA has agreed to accept Conditional Marketing Authorization application for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results of DRAGON trial Conference call and webcast on Monday, November 10, 2025, at 4:30 p.m. ETSAN DIEGO, Nov. 10, 2025...